Clinical Trial Update: A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of PCSK9 inhibitor AK102 in patients with heterozygous familial hypercholesterolemia has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heterozygous Familial Hypercholesterolemia

Drugs mentioned

• AK102

Snippet

Sponsor: Akeso | Conditions: Heterozygous Familial Hypercholesterolemia | Phase 2 | Status: COMPLETED